Gene therapy is transforming the way we can treat many diseases, but immune responses to AAV vectors remain a critical challenge. Whether you're screening for pre-existing immunity, validating your vector, or preparing for regulatory submission, you need reliable, actionable data-and a partner who understands the stakes. .
Today, we're proud to launch our comprehensive AAV Immunogenicity Assay Platform.
This new offering combines three powerful assays into a fully customized safety solution to help you move forward with clarity and confidence.
Gene therapy is transforming the way we can treat many diseases, but immune responses to AAV vectors remain a critical challenge. Whether you're screening for pre-existing immunity, validating your vector, or preparing for regulatory submission, you need reliable, actionable data-and a partner who understands the stakes. .
Today, we're proud to launch our comprehensive AAV Immunogenicity Assay Platform.
This new offering combines three powerful assays into a fully customized safety solution to help you move forward with clarity and confidence.
Rapidly assess pre-existing immunity for key AAV serotypes (2, 5, 6, 8, 9) with our off-the-shelf products or get a customised assays for your specific vector.
Leverage the specificity of our tailored ELISA-based Total Antibody assays to assess pre-existing antibody-mediated immunity towards any serotype, including your own unique vector
Detect AAV vector-associated complement system activation with our ELISA-based AAV COMPL assay to reduce the risk of adverse events and gain a more complete and improved profile .
Each assay is available on demand or can be fully integrated into a custom solution tailored to your vector, indication, and development stage.
Our platform is designed for flexibility. Whether you're a biotech innovator, CRO, CDMO, or academic team, we offer: